In a patient with polycythemia and a hematocrit of 57% and hemoglobin of 19 g/dL, should therapeutic phlebotomy be performed?

Phlebotomy is Strongly Indicated for This Patient

With a hematocrit of 57% and hemoglobin of 19 g/dL, therapeutic phlebotomy should be performed immediately to reduce the hematocrit to below 45%. This recommendation is based on high-quality guideline evidence demonstrating that maintaining hematocrit <45% significantly reduces cardiovascular death and major thrombotic events 1, 2.

Evidence-Based Target and Rationale

The CYTO-PV trial established that maintaining hematocrit <45% versus 45-50% resulted in dramatically lower rates of cardiovascular death and major thrombosis (2.7% vs 9.8%, HR 3.91) 1. This finding forms the foundation of all current guideline recommendations from both European LeukemiaNet and NCCN 1, 2.

Your patient's hematocrit of 57% is significantly above the therapeutic target, placing them at substantially elevated thrombotic risk. The hemoglobin of 19 g/dL further confirms the need for urgent intervention.

Phlebotomy Protocol

Induction phase:

• Remove 300-450 mL of blood weekly or twice weekly until hematocrit <45% is achieved 1
• Monitor hematocrit before each procedure
• Continue until target is reached

Maintenance phase:

• Same volume per phlebotomy (300-450 mL)
• Frequency determined by hematocrit levels 1
• Goal: maintain hematocrit <45% continuously

Additional Mandatory Interventions

Beyond phlebotomy, all patients with polycythemia vera require:

• Low-dose aspirin (81-100 mg daily) unless contraindicated 1, 2
• Aggressive cardiovascular risk factor management 2

When to Consider Cytoreductive Therapy

While phlebotomy is indicated now, assess whether this patient also needs cytoreductive therapy (hydroxyurea or interferon) based on:

High-risk criteria (cytoreduction strongly recommended):

• Age ≥60 years 1, 2
• Prior thrombotic event 1, 2

Additional indications for cytoreduction:

• Poor tolerance to phlebotomy 1
• Frequent/persistent need for phlebotomy 2
• Symptomatic or progressive splenomegaly 1, 2
• Severe disease-related symptoms (pruritus, night sweats, fatigue) 2
• Platelet count >1500 × 10⁹/L 1
• Leukocyte count >15 × 10⁹/L 1

Important Caveats

For female patients: Consider a lower hematocrit target of 42% rather than 45%, as this may be more appropriate 2. The guidelines acknowledge that individualization may be needed based on sex and symptoms.

Iron deficiency: Phlebotomy will induce iron deficiency, which is actually therapeutic in polycythemia vera. However, if severe tissue iron deficiency causes detrimental symptoms (pica, mouth paresthesia, esophagitis, restless legs), iron supplementation may be indicated—but this then necessitates cytoreductive therapy to prevent hematocrit elevation 1.

Monitoring: Evaluate every 3-6 months for thrombosis, bleeding, disease progression, and need for cytoreductive therapy 2.

The evidence is unequivocal: phlebotomy to achieve and maintain hematocrit <45% is the cornerstone of polycythemia vera management and directly reduces mortality and morbidity from thrombotic complications 1, 3, 4.